Plain-English translation of NCT03770936 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether two blood pressure medications— and —can help slow liver scarring (fibrosis) in people with chronic hepatitis C. Researchers want to see if these medications, which are already used safely for other conditions, might protect the liver from developing more scar tissue over time. If successful, this treatment could offer a new way to help prevent serious liver damage.
Chronic hepatitis C can cause the liver to scar and harden over time, eventually leading to serious complications. Doctors are looking for affordable, well-tolerated ways to slow this scarring process, and these blood pressure medications show promise in early research.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to one of three groups: one taking daily, one taking daily, or a control group receiving no new medication. You'll take your assigned medication (or none, if in the control group) and visit the clinic for check-ups to monitor how your liver is responding. The study will measure changes in your liver scarring over time to see if the medication helps.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Egypt
Sponsor
Sherief Abd-Elsalam
Enrollment target
~45 participants
Started
October 2018
Primary completion
October 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
20 Years and older
Last updated on clinicaltrials.gov in December 2018.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sherief Abd-Elsalam, Ph D
Clinical pharmacy Department- Tanta University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.